Updated on 20 June 2012
An application to make DIFICID widely available in Australia has been filed with the Therapeutic Goods Administration, with the drug expected to be launched by June 2013.
Optimer Chief Executive Officer Pedro Lichtinger said he looked forward to DIFICID being widely available in Australia and New Zealand. "We are committed to enabling better outcomes for patients with this difficult to treat infection. I believe this is a truly innovative therapy providing a new patient option for an unmet medical need," he said.
DIFICID is approved by the US Food and Drug Administration for the treatment of Clostridium difficile-associated diarrhoea (CDAD) in adults 18 years of age or older. Likewise, the European Commission granted Marketing Authorisation to fidaxomicin for the treatment of adults with Clostridium difficile infections under the trade name DIFICLIR.